Clinical Trial Update: High Dose of Activated Recombinant Human Factor VII for Treatment of Mild/Moderate Joint Bleeds in Haemophilia Patients With Inhibitors [Phase 4]

View source ↗

Summary

Phase 4 trial update evaluating high-dose activated recombinant human factor VII to treat mild to moderate joint bleeds in haemophilia patients with inhibitors.…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Haemophilia

Drugs mentioned

• NovoSeven RT (Recombinant activated factor VII)

Snippet

Sponsor: Novo Nordisk A/S | Conditions: Congenital Bleeding Disorder, Haemophilia A With Inhibitors | Phase 4 | Status: COMPLETED